TNFRSF17 and plasma cell myeloma: In an early-phase exploratory trial enrolling patients with high-risk newly diagnosed multiple myeloma, CD19-specific CAR-T cells and BCMA-specific CAR-T cells were sequentially infused after autologous stem cell transplantation, followed by lenalidomide maintenance therapy [68].